April 03, 2025

Atamyo completes the dose-finding study in Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) and obtains US Rare Pediatric Disease Designation for ATA-100

Evry, France (April 3, 2025) –Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies, announced the completion of the dose-escalation phase of its Phase 1b/2b clinical […]

Read more

September 12, 2024

Professor Isabelle Richard has received the Fifth Annual LGMD2i Pioneer Award from Cure LGMD2i Foundation and the Speak Foundation

This recognition is for Isabelle Richard’s groundbreaking research on LGMD. Isabelle Richard, Ph.D., is Research Director at National Center of Scientific Research (CNRS) in France and head of the Progressive Muscular Dystrophies Laboratory at Genethon. We are […]

Read more